10-K/A 1 cytta10ka93013final.htm FORM 10-K/A Cytta Corp.



U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K /A

Amendment No. 1


(Mark One)

[x]

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For Fiscal Year Ended: September 30, 2013

OR

[  ]

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to­­­­­­­­­­


Commission file number

333-139699

   CYTTA CORP.   

 (Exact name of small business issuer as specified in its charter)


Nevada

 

98-0505761

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

6490 West Desert Inn Road, Las Vegas, NV

 

89146

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number:  (702) 307-1680

Securities registered under Section 12(b) of the Act:  None

Securities registered under Section 12(g) of the Act:  None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  

[  ]  Yes

[X]  No


Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.  Yes [X]     No [  ]    

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]     No [  ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of the “large accelerated filer,” “accelerated filer,” “non-accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.   (Check one):

Large Accelerated Filer [  ]

Accelerated Filer [  ]

Non-Accelerated Filer [  ]

Smaller reporting company [X]  

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ]   No [X]

As of January 13, 2014, there were 25,701,904 shares of the registrant's common stock, par value $0.001, issued and outstanding. Of these, 17,459,789 shares are held by non-affiliates of the registrant. The market value of securities held by non-affiliates was $1,745,979 on January 15, 2014.  

DOCUMENTS INCORPORATED BY REFERENCE

Not Applicable



1





Explanatory Note


This Amendment No. 1 on Form 10-K/A (this "Amendment") amends the Annual Report on Form 10-K of Cytta Corp. (the "Company") for the fiscal year ended September 30, 2013, originally filed with the Securities and Exchange Commission (the "SEC") on January 17, 2014 (the "Original Filing"). We are filing this Amendment for the purpose of providing an XBRL version and correcting the Officers and Directors of the Company at the time of the filing and certain share calculations and information related thereto. The Original Filing was not submitted in XBRL and accidentally reflected the Officers and Directors as of the previous year and their information. Except as expressly set forth in this Amendment, we are not amending any other part of the Original Filing. This Amendment continues to speak as of the date of the Original Filing, and does not reflect events occurring after the filing of the Original Filing or modify or update any related or other disclosures unless expressly noted otherwise. Accordingly, this Amendment should be read in conjunction with the Original Filing and with our other filings made with the Securities and Exchange Commission subsequent to the filing of the Original Filing, including any amendments to those filings. The filing of this Amendment shall not be deemed an admission that the Original Filing when made included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading.





2





Table of Contents


 

Cautionary statements regarding forward-looking information

4

PART I.

 

 

ITEM 1.

Business

5

ITEM 1A.

Risk Factors

11

ITEM 1B.

Unresolved Staff Comments

11

ITEM 2.

Properties

11

ITEM 3.

Legal Proceedings

11

ITEM 4.

Submission Of Matters To A Vote Of Security Holders

11

PART II.

 

 

ITEM 5.

Market For Registrant's Common Equity, Related Stockholder Matters And Issuer Purchases of Equity Securities

12

ITEM 6.

Selected Financial Data

14

ITEM 7.

Management's Discussion And Analysis Of Financial Condition And Results Of Operations

15

ITEM 8.

Financial Statements And Supplemental Data

17

ITEM 9.

Changes In And Disagreements With Accountants On Accounting And Financial Disclosure

17

ITEM 9A(T.)

Controls And Procedures

18

ITEM 9B.

Other Information

19

PART III.

 

 

ITEM 10.

Directors, Executive Officers, And Corporate Governance

19

ITEM 11.

Executive Compensation

21

ITEM 12.

Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters

22

ITEM 13.

Certain Relationships And Related Transactions, And Director Independence

24

ITEM 14.

Principal Accounting Fees And Services

24

PART IV.

 

 

ITEM 15.

Exhibits And Financial Statement Schedules

25





3






CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION

Except for historical information, this report contains forward-looking statements.  Such forward-looking statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses.  Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes” and similar language.  Our actual results may differ significantly from those projected in the forward-looking statements.  Factors that might cause or contribute to such differences include, but are not limited to, those discussed in the sections “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  You should carefully review the risks described in this Annual Report and in other documents we file from time to time with the Securities and Exchange Commission (the “SEC”).  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document.


Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.


All references in this Form 10-K to the “Company,” “Cytta,” “we,” “us” or “our” “registrant” are to Cytta Corp.




4





PART I


ITEM 1.  BUSINESS.

Business Development

Cytta Corp. was incorporated in the State of Nevada on May 30, 2006, and our fiscal year-end is September 30th. The company's corporate offices are located at 6490 West Desert Inn Road, Las Vegas NV 89146, and the telephone number is (702) 307 1680.

Cytta Corp delivers real-time and accurate health and wellness information utilizing any manufacturers’ Bluetooth monitoring device through WiFi, an unlocked Android Smartphone, and soon through Satellite connectivity, to any existing or customized Electronic Medical Record (EMR) platform.  The Cytta Connect solution is completely HIPAA secure, 100% reliable, easily portable, and customizable using the equipment that clients want. Cytta Connect Special Purpose Network and Cloud based Electronic Biometric Record (EBR) connects anyone, anywhere, anytime. Cytta makes any Bluetooth health, wellness or fitness device report their data from remote locations seamlessly via our cloud based Instant EBR & proprietary Mobile Network for instant real-time data access.

Cytta had for several years been designing and building an ecosystem that would allow any Bluetooth device to automatically send its data to our specially provisioned Android SmartPhone and then instantly pass that data unto a cloud based Electronic Medical Record, which is automatically populated with the client’s readings and information. The completion of the Cytta Connect system now allows patients, their caregiver or medical provider to review and monitor on an ongoing basis.  

Cytta’s technology called Cytta ConnectTM is a completely open source Special Purpose Medical Network.  Cytta’s unique and proprietary system allows us to connect all forms of Bluetooth enabled health, wellness or fitness monitoring devices (FDA and Non FDA) seamlessly through an unlocked Android Smartphone and deliver the data in real-time to a cloud based data repository which can easily be customized to our client’s requirements.  

The Cytta Connect system works seamlessly everywhere there is cellular service.  Cytta Connect is currently implementing systems to monitor, COPD, Asthma, Diabetes, Hypertension and Obesity as well as several major causes of hospital readmission.

Cytta Corp. had revenues of $2,800 during the year ended September 30th, 2013 and upon completion of our technology began initial sales and marketing operations.   We have now commenced preliminary marketing of our remote patient monitoring (RPM) system called Cytta Connect and have generated revenue therefrom. We have sustained losses since inception while developing our Cytta Connect system and had previously relied primarily upon the sale of securities and loans from our corporate officers and directors for funding.

Cytta has never declared bankruptcy, been in receivership, or involved in any kind of material legal proceeding. Cytta, its directors, officers, affiliates and promoters have not and do not intend to enter into negotiations or discussions with representatives or owners of any other businesses or companies regarding the possibility of an acquisition or merger.

Business of Issuer

Cytta’s technology called Cytta ConnectTM is the world’s first open source Special Purpose Medical Network.  Cytta’s proprietary technology disrupts and innovates the 2 fastest growing health markets that need to collect data & reduce costs: Our unique and proprietary system allows us to connect all forms of Bluetooth enabled monitoring devices (FDA and Non FDA) seamlessly through an Android Smartphone and deliver the data in real-time to a cloud based data repository which can easily be customized to our client’s requirements.  



5





Cytta Connect is a Remote Data Capture system connecting Bluetooth devices to online Electronic Biometric Records (EBR). Our remote data capture system works over our Special Purpose NetworkTM, a proprietary Global Mobile, Satellite, WiFi, and Cloud-based data Network that connects all Bluetooth medical, fitness and wellness devices to Cytta’s open source EBR. Our open source EBR is for use by patients, doctors, caregivers, health insurers (Professional Care) with our preprogrammed Cytta smartphones, and any wellness or fitness user (Consumer) with any cellular carrier’s smartphone.

We serve two very large markets:  

1) Professional Care (Double FDA approved medical devices) works with our specially programmed smartphones and provides care for the chronically ill who need to be remotely monitored. Caregivers have diagnostic capability using our Instant EBR and secure biometric data transfers via Cytta’s Special Purpose Network. We interconnect patients, their data and caregivers. We manage vital sign monitoring of chronic care customers and integrate FDA compliant data results for use by Physicians, Hospitals, Accountable Care Organizations and Employers. .

2) Consumer Wellness (Any and all Bluetooth devices) works with any Carrier’s mobile phone and leverages our proprietary Universal Application and Instant EBR to support Wellness & Fitness consumers. We aid in managing Weight Loss, Wellness, Fitness, Health Data Collection for medical review, Specialized Health Social Network, Personal Safety & Security.

The Cytta ConnectTM system is a cost effective system that works with any manufacturers’ off the shelf Bluetooth enabled monitoring device and any Android Smartphone.  The Cytta Connect system works seamlessly everywhere there is cellular service.  Cytta Connect is currently implementing systems to monitor, COPD, Asthma, Diabetes, Hypertension and Obesity as well as several major causes of hospital readmission

Cytta was originally formed in 2006 to be a web based service provider for general contractors.  This business was abandoned and the Company in December 2008 merged with Ophthalmic International, Inc. (“OI”), a Nevada corporation that manufactured and marketed a medical fixation device with a patented designed suction ring that treats Open Angle and Pigmentary glaucoma. On May 8, 2009, Cytta entered into an Agreement (the “Agreement”), pursuant to which the transaction was cancelled. These transactions are more fully described in our reports on Form 8-K filed with the Securities and Exchange Commission on December 12, 2008, May 12, 2009, and May 20, 2009, respectively.

On June 9, 2009, the Company determined it wished to stay in the medical products industry and pursued an opportunity to enter into the remote patient monitoring (RPM) sector.  On June 18th, 2009, the Company entered into a Licensing Agreement with Lifespan, Inc. a Nevada Corporation.  Through a series of transactions and business developments commencing in 2002 Lifespan had acquired the expertise and licenses to manufacture, distribute and market various technology based internet and telephony based access and computing products and services, consisting of internet access devices, related software and hardware and a series of medical peripherals designed and adapted to provide remote patient monitoring (RPM) of home based and remote patients.  

Under the terms of the Agreement with Cytta, Lifespan granted the Company the exclusive license to manufacture, sell, distribute, operate, sub-license and market these internet and telephony access devices, products and services in the United States.  The Company has been utilizing the License to develop a model for the internet and telephony access devices which can incorporate the numerous technology advances which are currently available and has determined to utilize android based smartphones and tablets as the connectivity devices.  In exchange for the license, Lifespan has received 400,000 post-split shares of the Company’s common stock, plus a license fee equal to one half of one percent (.5%) of the net revenue derived from the sale and use of their products and services.  This transaction is more fully described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2009.



6






On November 10th, 2010, the Company entered into an MVNO Mobile Virtual Network Operator Agreement (herein “MVNO Agreement”) with Vonify Inc. of Toronto, Canada and Georgetown, Grand Cayman Island, BWI (herein “Vonify”) and MVNO Mobile Virtual Network Operator Corp (herein “MVNO”) of New Westminster, Canada (“MVNO Corp.”) a company owned and controlled by Mr. Gary Campbell an Officer and Director and controlling shareholder of Cytta for a license to provide all the “Services” of the Vonify Network to third parties, in the medical marketplace in the USA as a Special Purpose Medical Network.  Cytta may only resell Services to third parties who are also End Users and such third parties may not further resell the Services.  Cytta is expressly permitted to use and develop their own applications and programing for the phones and may develop and utilize applications, which require modification of the “native” or “core” programing of the Smartphones provided it does not have a deleterious effect upon the Network.

The Vonify Network includes those integrated mobile switching facilities, servers, cell sites, telecom and internet connections, billing systems, validation systems, gateways, landline switches and other related facilities used to provide the Services.   Vonify operates the network utilizing the C & F Block Spectrum Licenses and associated roaming agreements and all the land, towers and antennas along with the associated network agreements.  

Pursuant to Cytta’s MVNO agreement with Vonify, the Services to be marketed by Cytta are defined as wireless telecommunications services for the Global System for Mobile (GSM) communications.   The Company has finalized the testing of the Vonify network in the US utilizing Vonify SIM cards installed on numerous brands of android smartphones and tablets deployed in various parts of the US.  After comprehensive testing, the Cytta network was found to be fully functional and compliant in regards to voice, data and SMS connectivity.  The network is suitable in all aspects for utilization by Cytta for the movement of medical information gathered from Bluetooth enabled remote medical monitoring devices.  The Cytta Medical smartphones and tablets are also fully functional voice, data, and SMS cell phones.  

In exchange for the MVNO Agreement, Cytta issued 833,334 post-split shares of the Company’s common stock to Vonify Inc.  This transaction resulted in Vonify Inc. becoming a greater than 10% shareholder of the Company at the time.  Mr. Michael Scott, a Director of the Company, is the controlling shareholder of Vonify Inc. This transaction is more fully described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 29, 2010.

In an effort to respond to data security concerns related to the transmission of information through a mobile communications network, on June 24th, 2011, the Company entered into a Joint Venture and Value Added Reseller Agreement and a final Exclusive License Agreement on August 18th, 2011 (herein the “Agreement”) with Promia, Inc. of San Francisco, CA (herein “Promia”) to exclusively market on a worldwide basis Promia’s software and hardware development services and technologies. This transaction is more fully described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2011.

On January 25th, 2012, the Company’s Board ratified an executed Wireless Data Machine to Machine (M2M) Communications Agreement with ATT Mobility II, LLC on behalf of its affiliates AT&T or AT&T Mobility (herein AT&T) pursuant to the terms of which Cytta agrees to purchase from AT&T and AT&T agrees to sell to Cytta wireless service for use in machine to machine communications on AT&T’s Wireless Data Network.  Through AT&T, Cytta can offer a nationwide Data GSM/GPRS footprint across 100 percent of the AT&T service area. GSM also provides global compatibility resulting in more international roaming potential.  Cytta has currently activated its first AT&T SIMs through its VPN and is evaluating their market potential.  Additional setup, activation and details are currently being explored between the parties. This transaction is more fully described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on January 31st, 2012.



7






Since the acquisition of the Lifespan technology, and the rights to utilize the Vonify Wireless Network through the Vonify MVNO Agreement, and the AT&T Data MVNO agreement, and the Agreements with the medical device manufacturers, the Company has now completed the development of a remote medical monitoring model or remote patient monitoring (RPM) system designed to deliver seamless, near real-time, medical data transmission from home to Insurer/Provider.  The Company’s system seamlessly collects the data generated by the portable or home based medical monitoring devices (such as blood pressure, scale, blood glucose, pulse oxygen etc.), utilizing Bluetooth connectivity. This medical data is sent via Bluetooth from the medical device to the Company’s Medical Smartphone, which is also located in the home and/or held by the patient.

The Company’s Medical Smartphone, contains proprietary device resident or “native” programming, consisting of a “Firmware Client” or “Super App” developed by Connected Health Pte. Ltd. in conjunction with the Cytta Special Purpose Network and which is licensed to Cytta pursuant to the July 14, 2011 License Agreement.  This application for the phones is designed to automatically receive Bluetooth data and perform autonomous control and connectivity functions utilizing the voice, data and SMS capability of the Smartphone or tablet. Connected Health is a wireless health innovator committed to developing health monitoring connectivity solutions which when installed on the Cytta Medical Smartphone, automatically receives the medical data and utilizes the Company’s wireless telecommunication services, to transmit the data through the cellular network to Cytta’s proprietary online or Cloud based Cytta Data repository Dashboard called the ‘Instant EMRTM’.  

From the Online or Cloud based Cytta Data repository Dashboard or ‘Instant EMRTM’ the data can be utilized as part of the electronic medical monitoring systems (EMR’s) of the major Medical Groups (such as Insurance Companies, Disease Management Companies, Health Delivery Organizations, Health Plans, Home Health Agencies, Managed Care Organizations, Medical Groups and IPAs) who have placed the systems in the homes of their clients requiring remote patient monitoring.  These Medical Groups contract with Cytta and are responsible for installing, monitoring and financing the system in the homes of their clients who require monitoring.

The Company has currently entered into agreements with respected medical device manufacturers A&D Medical, Nonin Medical, ForaCare, and Entra Health, which have allowed Cytta to design our ecosystem to incorporate their double FDA approved medical monitoring devices to for measurement of Blood Pressure, Glucose Values, Weight, Temperature, Pulse, and Oxygen Saturation. The Company is now capable of adding any Bluetooth remote monitoring device to the Cytta Connect ecosystem whether FDA approved or Non FDA approved and is currently working to add PT/INR, ECG Rhythms, Respiration, and a personal emergency response system (PERS) into the Cytta Ecosystem.  

The Company and its licensing partner Connected Health Pte. Ltd. have now completed the development of the proprietary Firmware Client and have installed the technology on several Nexus One, HTC My Touch, HTC Wildfire, HTC Sense, Sony Xperia android smartphones.as well as with the Samsung and HTC tablets.  The testing and integration of the combination Smartphone/tablets and Firmware Client, which has collectively been described as the Cytta Medical Smartphone or the Cytta Medical Tablet, with the double FDA blood pressure, weight scale, pulse/oximetry and blood glucose devices, has been completed and are all functioning seamlessly.  The Company has completed the development of the relational database and the GUI developed therefrom consisting of ‘Online Data Presentation Screens” Dashboard or ‘Instant EMRTM’ to represent the data captured by the system for its clients.  

The Company began its first trial installations of the complete Cytta Ecosystems in September 2011 in the US, with two Medical Group clients wishing to utilize and or participate in the Company’s “medical monitoring ecosystem’. In March 2012 the Company commenced its first major installation and product evaluation with a major medical Insurance Co/Payor.  The Company also delivered its second round of orders to its first two medical group clients and has received notice of upcoming further installations.

Upon successful conclusion of the Insurance co/Payor Pilot Program evaluation, the Company planned to begin full deployment of its systems and commence operations as a Medical Health Service Provider (MHSP). In November 2012 the Company received the 6 Month Pilot Program Whitepaper dated September 30, 2012 independently prepared by the major medical Insurance Co/Payor with whom the Pilot program was conducted.  The conclusions of their Independent Whitepaper stated,



8






“This trial demonstrated the ability to significantly reduce costs for high risk patients through use of the CYTTA Connect Ecosystem.  The trial demonstrated the ability to quickly achieve cost savings, decrease resource utilization, improve care coordination, and increase adherence to evidence based guidelines.  Adherence to evidence based guidelines is increasingly important as CMS 5 STAR ratings garner importance.

Care costs were reduced on average by $11,078 [or $1,846 per member per month] for each trial participant.  This trial did not specifically address long term cost of care.  However, these patients were selected for the inabilities of the existing healthcare system and care coordination programs to cost effectively address their short or long term healthcare needs.  One trial participant noted he realized more value and benefit in 2 months of trial participation compared to his previous 17 months of participation in the best available care coordination services.  A quite handsome return on investment is present if the care coordination system is priced at less than $2,000 per year.  

This trial also demonstrated that home biometric monitoring using the CYTTA Connect Ecosystem can be easily introduced, dispensed and utilized in the home setting.  Care team training was easily completed.  CYTTA Connect was easy for patients and care coordinators to learn and effectively use.  Technical troubleshooting was prompt and effective.  

Improved patient engagement and ability to self-manage care will become increasingly important and require new resource allocation because CMS will soon require Stage II Readiness participation.  Through repeated collection and review of biometric data patients learn how to titrate medications and adjust behaviors to achieve target goals which is a cornerstone of CMS 5 STAR performance and CMS Stage II Readiness.   Patients and the care coordination team are prompted by alerts to evaluate and to intervene in real time.  This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics through self-management.  Additionally, improved achievement of target metrics produces significant provider and care team satisfaction.  Efforts of both become both more effective and more efficient.  

Effective use of the CYTTA Connect Ecosystem requires the managing physicians to develop and communicate care plans and standing orders to adjust medications to achieve target goal.  Too often the goals of care and associated care plans including medication administration are poorly communicated or not present.  Patients travel through various sites of service and levels of care without a clear understanding of the expected behaviors and medication usage to be executed in the home setting.  CYTTA Connect in conjunction with care coordination resolves this deficit and allows for care plan and medication revision as the patient disease processes change in the home environment.  Through repeated measurement and with focused care coordination the patient learns how to better manage their health care needs.  This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics.  This also produces a more satisfied patient, physician, and care coordination team.  

This trial discovered patients view CYTTA Connect and remote telemonitoring as a special benefit to patients who are encouraged to retain their relationship with Heritage to continue to access and build their personal health database.  Patients develop a special relationship with their care coordination team. The patients viewed CYTTA Connect and care coordination activities as a value rather than an intrusion because information and advice generated by the trial were specific to the patient and time sensitive.  

This trial enabled physicians and care coordinators to more effectively manage a larger number of patients.  Current care coordination ratios can be expanded by 20% using biometric remote telemonitoring through reduced telephone tag and elimination of unfocused, subjective, generic discussions with patients.  Instead specific biometric data, medication usage, review of the active care plan, and comparison to target metrics produces a focused discussion.  Patients and care coordinators



9





are taught through rapid cycle improvement to Plan, Do, Study, and ACT.  Barriers to successful self-management are identified and addressed.  Patients now learn how to revise and update their care management in the home setting rather than a physician office, emergency or hospital room followed by an attempt to translate and implement the care plan in their home setting upon discharge.  Patient contacts have become value oriented with immediate return on investment to the care coordinators and patient.”  

As can be seen from the above conclusion, the Company’s integrated and completely autonomous system provides numerous advantages over current systems, as well as a pricing structure designed to generate a positive return on investment (ROI) for the Medical Groups utilizing the system.  To this end the Company is currently demonstrating and actively marketing the Cytta Connect system to numerous Medical Group and Institutional clients wishing to utilize and or participate in the Company’s “medical monitoring ecosystem”. Cytta currently has limited operating costs and expenses at the present time due to our relatively new business activities. However we anticipate significantly increasing our activities as a result of the first sales of our systems and the installation thereof.

We have entered into certain management and consulting contracts with our senior Officers and non-affiliated consultants who will be providing business services to the Company in the health care arena. Additionally, we will be required to raise significant capital over the next twelve months, in connection with our operations resulting from our marketing Agreements. We have engaged in significant product research and development over the past year while the technology and system was being developed. The Company’s business may cause us to engage in further research and development in the foreseeable future. We have no present plans to purchase or sell any plant or significant equipment although we will have to acquire some equipment related to the marketing Agreements. We also have immediate plans to add employees and we will continue to do so in the future as a result of the operations related to the marketing of our systems.


Patents, Trademarks and Licenses, Franchises, Concessions, Royalty Agreements or Labor Contracts

 

We presently utilize no patents, licenses, franchises, concessions, royalty agreements or labor contracts in connection with our business with the exception of the license and royalty agreement with Lifespan Inc. and the licenses from Vonify Inc., MVNO Mobile Virtual Network Operator Corp., AT&T, Promia Inc. and Connected Health Pte. Ltd. described above.

 

Research and Development

 

During the fiscal year ended September 30, 2013 we paid $-0- in expenditures on research and development and during the fiscal year ended September 30, 2012, we paid $715,711 expenditures on research and development.

 

Employees

 

As of January 13, 2014 the Company has two employees.


Reports to Security Holders


The Company is not required to provide annual reports to security holders.


We are subject to the reporting requirements of the Securities and Exchange Commission (“SEC”) and we file reports including, but not limited to, Annual Reports of Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Proxy Statements on Schedule 14.


The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street N.E., Washington, D.C. 20549.  The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC and the address of that site is www.sec.gov.



10






ITEM 1A.  RISK FACTORS


Because we are a “smaller reporting company” as that term is defined by the SEC, we are not required to present risk factors at this time.


ITEM 1B.  UNRESOLVED STAFF COMMENTS


None.


ITEM 2.  PROPERTIES


Cytta's principal place of business and corporate offices are located at 6490 West Desert Inn Road, Las Vegas, NV, 89146 and the telephone number is (702) 307-1680. The Company pays $1,500 a month rent on a month to month basis.


Cytta does not currently have any investments or interests in any real estate, nor do we have investments or an interest in any real estate mortgages or securities of persons engaged in real estate activities


ITEM 3.  LEGAL PROCEEDINGS


No material legal or any governmental proceedings are presently pending or, to our knowledge, threatened, to which we are a party.


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


On April 25, 2013 the Company received notice from the Financial Industry Regulatory Authority (FINRA) they had received documentation necessary to effect a Reverse Stock Split. This corporate action was announced on April 26, 2013 and took effect at the open of business on April 29, 2013.

On April 9, 2013, Cytta Corp (the Company), received confirmation from the Secretary of State of the State of Nevada the Certificate of Change Pursuant to NRS 78.209 (the Certificate of Change) to the Amended and Restated Articles of Incorporation to effect a reverse split and par value increase of the Company’s Common Stock, $0.00001, par value per share (the Common Stock), at a ratio of 1-for-300 with all fractional shares rounded up to the next whole share (the Reverse Stock Split) was duly filed on April 9, 2013 to be effective April 29, 2013. After the Reverse Stock Split, the Company had approximately 12,630,489 common shares $0.001 par value outstanding. Pursuant to the Reverse Stock Split, the number of authorized shares of the Company’s Common Stock was reduced to 13,000,000 shares of Common Stock.

On April 10, 2013, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation pursuant to NRS 78.385 and 78.390 (the Certificate of Amendment) to increase the number of authorized shares of the Company’s Common Stock from 13,000,000 to 100,000,000 shares (the Capital Increase Amendment) on April 29, 2013 following the Reverse Stock Split.



11






PART II


ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES


Market Information


Since September 10, 2007, our Common Stock had been listed for quotation on the Over-the-Counter Bulletin Board OTCBB, under the symbol “CYCA”.  The OTCBB is now the FINRA.BB.  In 2011 the Company’s market maker, for cost reasons, removed quotation of securities from the OTCBB platform, causing Cytta along with numerous other securities to be automatically moved to the OTCQB even though they were current with their reporting obligations with the SEC under the Securities Exchange Act of 1934. OTCQB is a part of OTC Markets for Reporting Issuers and is a Recognized Stock Exchange.  It is the premier venture marketplace for companies that are current in their reporting with a U.S. regulator. OTCQB securities may also be quoted on the FINRA BB.


The following table sets forth the high and low closing bid prices for our Common Stock for the fiscal quarters indicated as reported on the OTCBB and OTCQB by the NASDAQ Composite Feed or other qualified interdealer quotation medium. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

 

Quarter Ended

 

High Bid

 

Low Bid

 

 

 

 

 

 

 

September 30, 2013

June 30, 2013*

March 31, 3013

December 31, 2012


September 30, 2012

 

$0.20

$0.27

$0.0008

$0.0008


$0.0013

 

$0.19

$0.27

$0.0008

$0.0007


$0.0011

 

June 30, 2012

 

$0.0019

 

$0.0017

 

March 31, 2012

 

$0.0021

 

$0.0019

 

December 31, 2011

 

$0.0008

 

$0.0007

 


September 30, 2011

 

$0.0013

 

$0.0013

 

June 30, 2011

 

$0.0021

 

$0.0017

 

March 31, 2011

 

$0.0011

 

$0.0009

 

December 31, 2010

 

$0.0012

 

$0.0009

 


September 30, 2010

 

$0.0023

 

$0.0013

 

June 30, 2010

 

$0.0042

 

$0.0015

 

March 31, 2010

 

$0.0049

 

$0.0004

 

December 31, 2009

 

$0.0018

 

$0.0004

 

 

 

 

 

 

 

August 11 through September 30, 2009**

 

$0.0012

 

$0.001

 

July 1 through August 11, 2009

 

$0.079

 

$0.02

 

June 30, 2009

 

$0.03

 

$0.02

 

March 31, 2009

 

$2.20

 

$2.20

 

December 4 through December 31, 2008***

 

$3.05

 

$3.05

 

October 1 through December 4, 2008

 

$0.25

 

$0.25

 

 

 

 

 

 

 

September 30, 2008

 

$0.25

 

$0.25

 

June 30, 2008

 

$0.25

 

$0.25

 

March 31, 2008

 

$0.25

 

 

$0.25

 

 

December 31, 2007

 

$0.25

 

 

$0.25

 

 




12





__________________

* After a 1 for 300 reverse stock split

** After a 20 for 1 forward stock split.

*** After a 4 for 1 forward stock split.


Holders

Of the 25,701,904 post split shares of common stock outstanding as of January 16, 2014, held by 185 shareholders of record, 10,280,762 shares are owned by our consultants, officers and directors.  


Dividends


There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends.  The Nevada Revised Statutes, however, do prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:



1.

we would not be able to pay our debts as they become due in the usual course of business; or


2.

our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.


We have not declared any dividends, and we do not plan to declare any dividend in the foreseeable future.


Recent Sales of Unregistered Securities


During the fiscal year ended September 30th, 2013, the Company sold securities that were not registered under the Securities Act of 1933 as follows:


January 1, 2013, the Company issued 670,833 post split shares of its $0.001 par value common stock at $0.38 for cash of $251,563, received during the fiscal year ended September 30, 2012, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  


February 21, 2013, the Company issued 633,333 post-split shares of its $0.001 par value common stock at $0.27 for services, received during the fiscal year ended September 30, 2013, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  The shares were not distributed and were subsequently returned for cancellation.


February 21, 2013, the Company issued 843,333 post split shares of its $0.001 par value common stock at $0.21 for cash, received during the fiscal year ended September 30, 2013, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  



13






February 21, 2013, the Company issued 300,000,000 presplit common shares or 1,000,000 post split common shares of its $0.001 par value common stock in to convert 3,000,000 of its $0.001 par value Class C Preferred shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.   These shares were issued in replacement of the purchaser’s original Class C Preferred shares which were not distributed and were subsequently returned for cancellation.


March 21, 2013, the Company issued 730,000,000 pre split common shares or 2,433,333 post-split common shares of its $0.001 par value common stock in to convert 7,300,000 of its $0.001 par value Class B Preferred shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  


March 22, 2013, the Company issued 441,818,600 presplit common shares or 1,472,729 post-split shares of its $0.001 par value common stock in to convert 4,418,186 of its $0.001 par value Class A Preferred shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.


June 24 2013, the Company issued 200,000 post-split common shares of its $0.001 par value common stock at $0.28 for services to be received during the fiscal year ended September 30, 2013, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  The services were not performed pursuant to the contract.


September 30, 2013, the Company issued 4,051,416 post-split common shares of its $0.001 par value common stock at $0.15 for cash, received during the fiscal year ended September 30, 2013, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  


September 30, 2013, the Company issued 5,820,000 post-split common shares of its $0.001 par value common stock at $0.20 for services, received during the fiscal year ended September 30, 2013, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  


October 15, 2013, the Company issued 3,000,000 post-split common shares of its $0.001 par value common stock at $0.23 for services, in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended. The Company did not engage in any general solicitation or advertising. The Company issued the stock certificates and affixed the appropriate legends to the restricted stock.  The shares were not distributed and were subsequently returned for cancellation.


None of the transactions involved any underwriters or underwriting discounts. All of the purchasers were deemed to be sophisticated financially and with regard to an investment in our securities.


Securities Authorized For Issuance Under Equity Compensation Plans


We do not have any equity compensation plans and accordingly we have no securities authorized for issuance under any such plans.


ITEM 6.  SELECTED FINANCIAL DATA


Not applicable.



14





ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described. This discussion contains forward-looking statements. Please see “Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements.

The following discussion and analysis of the Company’s financial condition and results of operations are based on the preparation of our financial statements in accordance with U.S. generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.


Results of Operations


We have generated $2,800 in revenues from our business operations for the year ended September 30, 2013 and have incurred $ 2,267,653 in operating expenses through the year then ended.

The following table provides selected financial data about our company for the fiscal year ended September 30, 2013 and 2012, respectively.  

Balance Sheet Data

September 30, 2013

September 30, 2012

Cash and cash equivalents

 $                     188,068

 $                            36,080

Total assets

 $                     245,704

 $                            96,295

Total liabilities

 $                     476,837

 $                          684,031

  Shareholders' equity (deficit)            $                     (23,133)        $                         (587,736)

          

  

Our cash in the bank at September 30, 2013 was $188,068.  Net cash provided by financing activities during the year through September 30, 2013 was $468,300.

Plan of Operation

Cytta has for several years been designing and building an ecosystem that would allow any Bluetooth device to automatically send its data to our specially provisioned Android SmartPhone and then instantly pass that data unto a cloud based Electronic Medical Record, which is automatically populated with the client’s readings and information. The goal of the Cytta Connect system was to allow patients, their caregiver or medical providers to review and monitor their progress remotely on an ongoing basis.

On June 18th, 2009, the Company entered into a Licensing Agreement with Lifespan, Inc.  Through a series of transactions and business developments commencing in 2002, Lifespan had acquired the expertise and licenses to manufacture, distribute and market various technology-based internet access and computing products and services, consisting of internet access devices, related software and hardware and a series of medical peripherals designed and adapted to provide remote non-diagnostic monitoring of home based and remote patients.  Under the terms of the Agreement with Cytta, Lifespan granted the Company the exclusive license to manufacture, sell, distribute, operate, sub-license and market these internet access devices, products and services in the United States.  The Company plans to utilize the License to develop a model for the internet access devices which can incorporate the numerous technology advances which are currently available and is currently pursuing this avenue

On November 10th, 2010, the Company entered into an MVNO Mobile Virtual Network Operator Agreement (herein “MVNO Agreement”) with Vonify Inc. of Toronto, Canada and Georgetown, Grand Cayman Island, BWI (herein “Vonify”) and MVNO Mobile Virtual Network Operator Corp (herein “MVNO”) of New Westminster, Canada for a license to provide all the “Services” of the Vonify Network to third parties, in the medical marketplace in the USA.  The Vonify Network includes those integrated mobile switching facilities, servers, cell sites, telecom and internet connections, billing systems, validation systems, gateways, landline switches and other related facilities used to provide the Services.   The Services to be marketed by Cytta are defined as wireless telecommunications services for the Global System for Mobile (GSM) communications.     



15






Since the acquisition of the Lifespan Technology, and the MVNO Agreement, the Company has a remote medical monitoring model designed to deliver seamless, near real-time, medical data transmission, through Bluetooth connectivity, utilizing the Company’s wireless telecommunication services, to major medical payor/providers back end electronic medical monitoring systems (EMR’s) with a pricing structure sufficient to generate a positive return on investment (ROI) for the clients.  


The Company and its licensing partner have now completed the development of the proprietary Firmware Client and have installed the technology on several Nexus One, HTC My Touch, HTC Wildfire, HTC Sense, Sony Xperia android smartphones.as well as with the Samsung and HTC tablets.  The testing and integration of the combination Smartphone/tablets and Firmware Client, which has collectively been described as the Cytta Medical Smartphone or the Cytta Medical Tablet, with the blood pressure, weight scale, pulse/oximetry and blood glucose devices has been completed and are all functioning seamlessly.  The Company has completed the development of the ‘Online Data Presentation Screens” Dashboard or ‘Instant EMRTM’ to represent the data captured by the system for its clients.  


The Company began its first installations of the complete Cytta Ecosystems in September 2011 in the US, with two Medical Group clients wishing to utilize and or participate in the Company’s “medical monitoring ecosystem’. In March 2012 the Company commenced its first major installation and product evaluation with a major medical Insurance Co/Payor.  The Company also delivered its second round of orders to its first two medical group clients and has received notice of upcoming further installations.


Upon conclusion of the Insurance co/Payor Pilot Program evaluation, the Company will begin full deployment of its systems and commence operations as a Medical Health Service Provider (MHSP). In November 2012 the Company received the 6 Month Pilot Program Whitepaper dated September 30, 2012 independently prepared by the major medical Insurance Co/Payor with whom the Pilot program was conducted. To this end the Company is currently in discussions with potential partners and/or clients wishing to utilize and or participate in the model or the ‘Company’s ‘medical monitoring ecosystem’.  The Company continues to advance the technology and its capabilities while discussing implementations in accordance with the Affordable Care Act.


Cytta currently has minimal operating costs and expenses at the present time due to our relatively new business activities. However we anticipate significantly increasing our activities as a result of the first sales of our systems and the installation thereof. We have entered into certain management and consulting contracts with our senior Officers and non-affiliated consultants who will be providing business services to the Company in the health care arena. Additionally, we will be required to raise significant capital over the next twelve months, in connection with our operations resulting from our marketing Agreements.


We have engaged in significant product research and development over the past years while the technology and system was being developed. The Company’s business may cause us to engage in further research and development in the foreseeable future. We have no present plans to purchase or sell any plant or significant equipment although we will have to acquire some equipment related to the marketing Agreements. We also have immediate plans to add employees and we will continue to do so in the future as a result of the operations related to the marketing of our systems.


Liquidity and Capital Resources


Our cash and cash equivalents balance as of September 30, 2013 was $188,068.

We currently have three clients utilizing our systems and are fully operational.  We currently have many potential clients evaluating our technology and systems.


We do not have sufficient funds on hand to pursue our business objectives for the near future or to commence operations without seeking additional funding. We currently do not have a specific plan of how we will obtain such funding.



16






Loans to the Company


We have been receiving loans from related parties of the Company to pay general operating costs in the form of convertible demand notes payable.  The convertible demand promissory notes do not bear interest.  As of September 30, 2013, $476,837 in notes was outstanding.  


We have minimal operating costs and expenses at the present time due to our limited business activities.  We will, however, be required to raise additional capital over the next twelve months to meet our current administrative expenses and to develop our operations. This financing may take the form of additional sales of our equity or debt securities to, or loans from, stockholders, or from our officers and directors.  There is no assurance that additional financing will be available from these or other sources, or, if available, that it will be on terms favorable to us.   


Going Concern


Our auditors have included an explanatory paragraph in their report on our financial statements relating to the uncertainty of our business as a going concern, due to our limited operating history, our lack of historical profitability, and our limited funds. We believe that we will be able to raise the required funds for operations and to achieve our business plan.


Off-Balance Sheet Arrangements


We have no off-balance sheet arrangements.

ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA


Our audited financial statements are included beginning immediately following the signature page to this report.  See Item 15 for a list of the financial statements included herein.


ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE


On May 1st, 2012, Cytta Corp., (the “Company”), provided notice to its independent registered public accounting firm, Sadler, Gibb & Associates, L.L.C. 291 South 200 West Farmington, UT 84025 (“SGA”), that the Company dismissed SGA, effective as of that date citing business reasons.  On May 2nd, 2012, Cytta Corp. (the “Company”), has retained Shelley International CPA, 1012 S. Stapley, Suite 114, Mesa, AZ 85204  as an independent registered public accounting firm for the Company’s financial statements going forward.


SGA’s audit report on the financial statements of the Company as of September 30th 2010 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, other than an explanatory paragraph regarding the Company’s ability to continue as a going concern.


Since March 12th, 2010, the date the Company engaged SGA as the Company’s independent registered public accounting firm and through the date of dismissal on May 1st, 2012, there were no disagreements on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused SGA to make reference in connection with SGA’s opinion to the subject matter of the disagreement.


In connection with the audited financial statements of the Company as of September 30, 2010 and for the period March 12th, 2010 through the date of dismissal on May 1st, 2012 there have been no reportable events with the Company as set forth in Item 304(a)(1)(v) of Regulation S-K.



17






ITEM 9A(T).  CONTROLS AND PROCEDURES


Disclosure Controls and Procedures


Under the supervision and with the participation of our senior management, including our chief executive officer and chief financial officer, Gary Campbell, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2013 (the “Evaluation Date”).  Based on this evaluation, our chief executive officer and chief financial officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the information relating to us, including our consolidated subsidiaries, required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.


Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting.  Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.  Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.  In evaluating the effectiveness of our internal control over financial reporting, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework.  Based on this evaluation, our officers concluded that, during the period covered by this annual report, our internal controls over financial reporting were not operating effectively. Management did not identify any material weaknesses in our internal control over financial reporting as of September 30, 2013; however, it has identified the following deficiencies that, when aggregated, may possibly be viewed as a material weakness in our internal control over financial reporting as of that date:

1.

We do not have an audit committee. While we are not currently obligated to have an audit committee, including a member who is an “audit committee financial expert,” as defined in Item 407 of Regulation S-K, under applicable regulations or listing standards; however, it is management’s view that such a committee is an important internal control over financial reporting, the lack of which may result in ineffective oversight in the establishment and monitoring of internal controls and procedures.

2.

We did not maintain proper segregation of duties for the preparation of our financial statements. We currently only have one officer overseeing all transactions. This has resulted in several deficiencies including the lack of control over preparation of financial statements, and proper application of accounting policies.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission (the “SEC”) that permit us to provide only management’s report in this annual report


Changes in Internal Control over Financial Reporting


There were no changes in our internal control over financial reporting during the year ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



18






Officers’ Certifications


Appearing as exhibits to this Annual Report are “Certifications” of our Chief Executive Officer and Chief Financial Officer.  The Certifications are required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”).  This section of the Annual Report contains information concerning the Controls Evaluation referred to in the Section 302 Certification.  This information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.


ITEM 9B.  OTHER INFORMATION

Not applicable.

PART III


ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE


The following table sets forth certain information, as of January 16, 2014 with respect to our directors and executive officers.


Directors serve until the next annual meeting of the stockholders; until their successors are elected or appointed and qualified, or until their prior resignation or , removal or term expiration .  Executive Officers serve for such terms as determined and ratified by our Board of Directors.  Each officer holds office until such officer’s successor is elected or appointed and qualified or until such officer’s earlier resignation or removal.  No family relationships exist between any of our present directors and officers.

N Name

Positions Held

Age

Date of Election or Appointment as Director

Gary Campbell

CEO, Chief Financial Officer, Treasurer, Secretary and Director

60

March 12, 2010

Erik Stephansen

President, Director

50

May 1st 2013


The following is a brief account of the business experience during the past five years or more of our directors and executive officers.

Gary Campbell

Mr. Campbell age 60, brings to the Company over three decades of small cap public company experience wherein he has assisted in the formation, operation and financing of numerous public companies and established ongoing contacts within the US and International telecommunications, medical and financial community. Mr. Campbell began his career as a securities, broadcasting and telecommunications attorney in Canada, where he oversaw a myriad of legal, securities and regulatory affairs ultimately becoming the Senior Partner of a corporate commercial law firm.  After selling his law firm in 1987, Mr. Campbell became a businessman finding, organizing, financing, and operating small public companies for his and his client’s interest.   



19






In 1982 Mr. Campbell was a Director, financier and primarily responsible for the IPO of International Verifact Inc. the inventor of the electronic point of sale terminal.  In 1991, Mr. Campbell was the Vice President, financier and a Director of Telemac Cellular Corporation a company involved in the development of cellular accounting data systems and technology, which lead to the development of the TRACfone an early stage MVNO and currently marketed throughout the USA .  Mr. Campbell then became the CEO and Director of Cancall Cellular Communications Inc., the public arm of Telemac Cellular, a major provider of cellular rental services utilizing the advanced Telemac technology. Cancall eventually became the national cellular rental administrator for AT&T.  Following this, Mr. Campbell became CEO of ScreenPhone Inc. a private company partnered with Samsung in the development of screen based software and applications for Samsung’s Anyweb internet appliance, and through ScreenMD, an affiliated Company, developed and implemented a first generation of internet based remote medical monitoring system for the Anyweb device. This technology was then acquired by Eclipse Entertainment Corp., a  movie company which Mr. Campbell was retained to reorganize, and which ultimately became Lifespan Inc. of which Mr. Campbell became CEO and a Director.   Mr. Campbell was retained to become CEO and Director of Rocketinfo Inc. and convert the company from a minor Oil & Gas company to a successful technology company.  Rocketinfo provided intelligent software tools that index, categorize and extract key concepts and data from current news and business information as well as a public search engine that offered the most robust capabilities in the industry for scanning and retrieving topical news and business information.

As part of his business activities, over the last 30 years, Mr. Campbell is often retained to assist clients with restructuring, and/or reorganizing small cap public Companies.   As part of those management consulting services he has been an Officer or Director of numerous small cap public companies in both the US and Canada.  Mr. Campbell has degrees in both Commerce and Law.


Erik Stephansen

Mr. Stephansen, 50, helped develop the concept for Cytta Connect and has devoted all of his personal energies to revamping the US Healthcare industry since 2010.  He is a former private equity Principal and Banker experienced in corporate development, network technology and management working with Cisco, Microsoft and other Fortune 500 companies. His passion is in aligning healthcare profits with healthier outcomes.


Mr. Stephansen was formerly a Principal with Castle Crow & Company, LLC, a San Francisco based Merchant Bank and Private Equity Advisor firm. As Principal, he formulated growth opportunities, estimated corporate value and sought platform investment opportunities and developed industry roll-up scenarios. Mr. Stephansen also led Special Projects where he oversaw energy ecosystem & health technology investments. His expert industry knowledge includes Applied Technologies, Power Tech, Medical Devices, Food Services, Manufacturing, and software service industries: Insurance, Staffing and Automated Services.


Mr. Stephansen has served in various managerial positions for CIBER, Inc., a publicly traded technology and software services company, Panda Restaurant Group, owner and operator of Panda Express national food chain, Tokai Bank and Bank of America.


Mr. Stephansen is a Business Economics graduate of University of California, Santa Barbara, studied marketing and urban planning at UC Berkeley and sustainable energy conversion at Stanford University.


Board of Directors


Our Board of Directors may designate from among its members an executive committee and one or more other committees.  No such committees have been appointed to date, due in part to the fact that we presently determining our business model.  Accordingly, we do not have an audit committee or an audit committee financial expert.  We are presently not required to have an audit committee financial expert and do not believe we otherwise need one at this time due to our lack of material business operations.  Similarly, we do not have a nominating committee or a committee performing similar functions.  Our Chief Executive and Financial Officer and Director Gary Campbell, serves the functions of an audit committee and a nominating committee.  We have not implemented procedures by which our security holders may recommend board nominees to us but expect to do so in the future, when and if we engage in material business operations.



20





Shareholder Communications


Currently, we do not have a policy with regard to the consideration of any director candidates recommended by security holders.  To date, no security holders have made any such recommendations.  


Code of Ethics


We have adopted a corporate code of ethics.  We believe our code of ethics is reasonably designed to deter wrong doing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of code violations; and provide accountability for adherence to the code. A copy of the code of ethics is attached as Exhibit 14.1, to our 10-KSB filed on December 27, 2007 with the Securities and Exchange Commission.  We will also provide to any person, without charge and upon request, a copy of the code of ethics.  Any such request must be made in writing to us at, 6490 West Desert Inn Road, Las Vegas, NV.


Compliance with Section 16(a) of the Exchange Act


Our common stock is not registered pursuant to Section 12 of the Exchange Act.  Accordingly, our officers, directors and principal shareholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.


ITEM 11.  EXECUTIVE COMPENSATION.


The following table sets forth information concerning the total compensation paid or accrued by us during the last two fiscal years ended September 30, 2013 to (i) all individuals that served as our principal executive officer or acted in a similar capacity for us at any time during the fiscal year ended September 30, 2011; (ii) all individuals that served as our principal financial officer or acted in a similar capacity for us at any time during the fiscal year ended September 30, 2013; and (iii) all individuals that served as executive officers of ours at any time during the fiscal year ended September 30, 2012 that received annual compensation during the fiscal year ended September 30, 2013 in excess of $100,000.


EXECUTIVE OFFICER COMPENSATION TABLE

Name and Principal Position     (a)

Year (b)

Salary (US$)  (c)

Bonus  (US$) (d)

Stock Awards(3) (US$) (e)

Option Awards (US$)   (f)

Non-Equity Incentive Plan Compensation   (US$)         (g)

Non-Qualified Deferred Compensation Earnings       (US$)           (h)

All Other Compensation   (US$)           (i)

Total   (US$) (j)

Gary Campbell (1) CEO, Treasurer,  Secretary

20132012

2011

 0          0

0         0

180,000(2)  120,000(2)

60,000(2)

 0           0

 0                     0

 0                      0

0                      0

0

180,000  120,000

60,000

Erik Stephansen, President

2013

0

0

187,500 (2)

0

0

0

0

187,500


(1)

Mr. Campbell was appointed President and Secretary effective March 12, 2010 and CFO and Treasurer November 15th, 2010

(2)

The compensation is authorized by the Company, but has been deferred until certain events occur.

(3)

All executive officer compensation previously disclosed during the last three fiscal years and no longer included in the above table have been rescinded, held in abeyance and/or cancelled by the Board.


We have stock based consulting agreements with our Officers, Directors and Board of Advisors.    We do not contemplate entering into employment agreements until such time as we begin profitable operations or complete a major financing.



21





The compensation discussed herein addresses all compensation awarded to, earned by, or paid to our named executive officers.


There are no other stock option plans, retirement, pension, or profit sharing plans for the benefit of our officers and directors other than as described herein.


Compensation of Directors

During the fiscal years ended September 30, 2013 and 2012, there were no arrangements between us and our directors that resulted in our making any payments to our directors for any services provided to us by them as directors.

ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.


(a) and (b) Security ownership of certain beneficial owners and management

At September 30, 2013, and subsequently, we had only two classes of outstanding voting securities, our common stock (referred to herein as the “Common Stock”) and our preferred stock (referred to herein as “Preferred Stock) of which three series are outstanding, Class A Preferred Stock, Class B Preferred Stock, and Class C Preferred Stock, all of which are convertible into restricted common shares if and when common shares are available. The Class A Preferred Shares have voting rights equivalent to twice the number of common shares into which the preferred shares may at some point be converted. The Class B and C Preferred Shares have voting rights equivalent to the number of common shares into which the preferred shares may at some point be converted.

The following tables set forth information regarding the ownership of our outstanding common stock as of the filing of this report by: (a) each person known by management to own, beneficially or of record, more than five percent (5%) of our common stock on an undiluted and diluted basis; (b) each director; (c) each executive officer named in the Compensation Table set forth later in this report; and (d) all of our directors and executive officers as a group.

The following tables assume, based on our stock records, there are 25,701,904 post split shares of our common stock, $.001 par value, currently issued and outstanding, and 333,350 Class A Preferred shares, $.001 par value, -0- Class B Preferred Shares, $.001 par value, and 600,000 Class C Preferred shares $.001 par value issued and outstanding, The Holders of the Class A Preferred shares presently have the right to vote two hundred (200) pre-split common shares for every one (1) Class A Preferred share held on all matters presented to the common stockholders.   The Holders of the Class B Preferred shares presently have the right to vote one hundred (100) pre-split common shares for every one (1) Class B Preferred share held on all matters presented to the common stockholders. The Holders of the Class C Preferred shares presently have the right to vote one hundred (100) pre-split common shares for every one (1) Class C Preferred share held on all matters presented to the common stockholders.

The Class A Preferred Holders are not required to convert their Class A Preferred shares into common stock prior to voting at any meeting of the shareholders or on any matter presented to the common shareholders.  The Class B Preferred Holders are not required to convert their Class B Preferred shares into common stock prior to voting at any meeting of the shareholders or on any matter presented to the common shareholders. The Class C Preferred Holders are not required to convert their Class C Preferred shares into common stock prior to voting at any meeting of the shareholders or on any matter presented to the common shareholders. As indicated above, as of the filing of this report there are 333,350 Class A Preferred shares outstanding, which convert into 111,116 post-split shares having 2 votes per share resulting in 222,234 post-split votes by the Class A Preferred Holders or less than 1 percent of the total shares of all classes entitled to vote on all matters presented to the common stockholders at any meeting. As indicated above, as of the filing of this report there are -0- Class B Preferred shares outstanding, which will result in -0- votes by the Class B Preferred Holders or -0- percent of the total shares of all classes entitled to vote on all matters presented to the common stockholders at any meeting. As indicated above, as of the filing of this report there are 600,000 Class C Preferred shares outstanding, which convert into 200,000 post-split shares having 1 vote per share resulting in in 200,000 post-split votes by the Class C Preferred Holders or less than 1 percent of the total shares of all classes entitled to vote on all matters presented to the common stockholders at any meeting. As such, an aggregate of 26,013,020 post-split shares and 26,124,138 votes are included in the fully diluted share and voting numbers should all Preferred shares be converted to common shares as of the date of this report.



22





SECURITY OWNERSHIP OF BENEFICIAL OWNERS

 

 

 

 

Name and Address of
Beneficial Owner

Shares of 
Common Stock
Beneficially Owned

Percent of 
Undiluted
Common Stock
Outstanding

Percent of
Fully Diluted 
Common Stock
(After Conversion of
Preferred Shares)

Lifespan, Inc.

PO Box 30211

Las Vegas, NV  89173

400,000

1.5 4 %

1.53%

Gary Campbell

6490 W Desert Inn Rd

Las Vegas NV 89146

2,884,313(1) 

11. 09 %

11.04%

Erik Stephansen

12386 Stockholm Way,

Truckee, CA 96161

2,083,333

8. 0 1%

7.97%

Total

5,367,646

20.64 %

20.54 %

(1)

Includes shares owned by corporations the votes attached to which Mr. Campbell can direct and which are thus deemed to be beneficially owned.


The following table sets forth information as of the date of this filing, with respect to the ownership of our common stock for all directors, individually; all executive officers named in the compensation table; all executive officers and directors as a group.

Name and Address of
Director or Executive Officer

Shares of 
Common Stock
Beneficially Owned

Percent of 
Undiluted
Common Stock
Outstanding

Percent of
Fully Diluted 
Common Stock

(After Conversion of

Preferred Shares)

 

Erik Stephansen

12386 Stockholm Way,

Truckee, CA 96161

2,083,333

8.11%

7.89%

Gary Campbell

6490 W Desert Inn Rd

Las Vegas NV 89146

2,884,313(1) 

11.22%

11.04%

Officers and Directors as a Group

4,967,646

19.33 %

18.93 %


(1)

Includes shares owned by corporations the votes attached to which Mr. Campbell can direct and which are thus deemed to be beneficially owned.



23






As used in this section, the term beneficial ownership with respect to a security is defined by Rule 13d-3 under the Securities Exchange Act of 1934 as consisting of sole or shared voting power (including the power to vote or direct the vote) and/or sole or shared investment power (including the power to dispose or direct the disposition) with respect to the security through any contract, arrangement, understanding, relationship or otherwise.

(c) Changes in control

Not applicable

(d)    Securities authorized for issuance under equity compensation plans  

Not Applicable.


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE


Related Transactions


As of September 30, 2013, the Company was obligated to related parties, for non-interest bearing convertible demand loans with a balance of $469,672.


Director Independence


We are not currently subject to listing requirements of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the board of directors be “independent” and, as a result, we are not at this time required to (and we do not) have our Board of Directors comprised of a majority of “Independent Directors.”


ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES


The aggregate fees billed to us by our principal accountant for services rendered during the fiscal years ended September 30, 2013 and 2012 are set forth in the table below:


Fee Category

Fiscal year ended September 30, 2013

Fiscal year ended September 30, 2012

Audit fees (1)

$ 12,500

$12,500

Audit-related fees (2)

$           0

$      0  

Tax fees (3)

$           0

$     0

All other fees (4)

$           0

$       0

Total fees

$ 12,500

$12,500


(1)

Audit fees consist of fees incurred for professional services rendered for the audit of financial statements, for reviews of our interim financial statements included in our quarterly reports on Form 10-Q and for services that are normally provided in connection with statutory or regulatory filings or engagements.


(2)

Audit-related fees consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our financial statements, but are not reported under “Audit fees.”  


(3)

Tax fees consist of fees billed for professional services relating to tax compliance, tax planning, and tax advice.


(4)

All other fees consist of fees billed for all other services.



24





Audit Committee’s Pre-Approval Practice.  

We do not have an audit committee.  Our board of directors performs the function of an audit committee.  Section 10A(i) of the Securities Exchange Act of 1934, as amended, prohibits our auditors from performing audit services for us as well as any services not considered to be audit services unless such services are pre-approved by our audit committee or, in cases where no such committee exists, by our board of directors (in lieu of an audit committee) or unless the services meet certain de minimis standards.


PART IV


ITEM 15.   EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.


Exhibits


The following Exhibits are being filed with this report on Form 10-K:

Exhibit No.

SEC Report Reference Number

Description

3.1

3.1

Articles of Incorporation of Registrant as filed with the Nevada Secretary of State on May 30, 2006 (1)

3.2

3.1

Amendment to the Articles of Incorporation of Registrant as filed with the Nevada Secretary of State on July 1, 2009 (2)

3.2

3.2

By-Laws of Registrant (1)

14.1

14.1

Code of Ethics (2)

21


*

List of Subsidiaries

31.1/31.2

*

Certification of Principal Executive Officer and Principal Financial Officer, pursuant to SEC Rules 13a-14(a) and 15d-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1/32.2

*

Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**



 


* Filed herewith.


** This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.


(1)

Filed with the Securities and Exchange Commission on December 28, 2006 as an exhibit, numbered as indicated above, to the Registrant’s registration statement on the Registrant’s Registration Statement on Form SB-2 (file no. 333-139699), which exhibit is incorporated herein by reference.

(2)

Filed with the SEC on July 6, 2009 as an exhibit, numbered as indicated above, to the Registrant’s Current Report on Form 8-K (SEC File No. 333-139699), which exhibit is incorporated herein by reference.

(3)

Filed with the Securities and Exchange Commission on December 27, 2007 as an exhibit, numbered as indicated above, to the Registrant’s Annual Report on Form 10-KSB (file no. 333-139699), which exhibit is incorporated herein by reference.




25






SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


CYTTA CORP.

Dated:  February 26, 2014

  By:

  

/s/ Gary Campbell

Gary Campbell, CEO, Chief Financial Officer and Director



Dated:  February 26, 2014

By:   /s/ Erik Stephansen

Erik Stephansen, President, Director


In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


SIGNATURE

TITLE

DATE


/s/ Gary Campbell

Gary Campbell

 CEO, CFO, Director


February 26, 2014


/s/ Erik Stephansen

Erik Stephansen


President, Director


February 26, 2014



26






PART IV – FINANCIAL INFORMATION


ITEM 15.

 FINANCIAL STATEMENTS






CYTTA CORP.


AUDIT REPORT OF INDEPENDENT ACCOUNTANTS

AND

FINANCIAL STATEMENTS


September 30, 2013 and 2012














27






Cytta Corp.

Table of Contents



Page


Audit Reports of Independent Accountants

F-1


Balance Sheets – September 30, 2013 and 2012

F-2


Statements of Operations for the years ended September 30, 2013 and 2012

F-3


Statements of Stockholder’s Equity (Deficit)

for the years ended September 30, 2013 and 2012

F-4


Statements of Cash Flows for the years ended September 30, 2013 and 2012

F-6


Notes to Financial Statements

F-7
















28






Shelley International CPA

Shelley International CPA

1012 S Stapley Suite 114

Mesa, AZ 85204-4272

(480) 461-8301

fx (480) 649-0622


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors

Cytta Corp.


We have audited the accompanying balance sheets of Cytta Corp. as of September 30, 2013 and 2012 and the related statements of operations, stockholders’ equity (deficit) and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.


We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.


In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Cytta Corp. as of September 30, 2013 and 2012, and the results of their operations and their cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.


The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 6 to the financial statements, the Company had a net loss of $2,258,422 for the year ended September 30, 2013 and accumulated losses of $5,566,721 as of September 30, 2013, which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 6. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.


/s/ Shelley International CPA


Mesa, AZ


January 17, 2014



F-1





Cytta Corp.

Balance Sheets

 

 

 

 

 

 

 

 

 

 

September 30,

September 30,

 

 

 

 

2013

2012

ASSETS

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

Cash and cash equivalents

$

188,068 

$

36,080 

 

Receivables

200 

 

 

Total Current Assets

188,268 

36,080 

 

 

 

 

 

 

OTHER ASSETS

 

 

 

 

 

 

 

 

 

MVNO License, (net of amortization)

6,480 

8,640 

 

Software license, (net of amortization)

2,751 

3,751 

 

Notes receivable

19,982 

23,835 

 

Loan to shareholder

17,500 

17,500 

 

Equipment, (net of depreciation)

10,723 

6,489 

 

 

Total Other Assets

57,436 

60,215 

 

 

 

TOTAL ASSETS

$

245,704 

$

96,295 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

CURRENT LIABILITIES

 

 

 

Accounts payable and accrued liabilities

$

7,165 

$

19,499 

 

Due to related parties

469,672 

664,532 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

476,837 

684,031 

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

Preferred stock:

 

 

 

 

100,000,000 shares authorized, $0.001 par value

 

 

 

 

 

933,350 and 15,651,536 issued and outstanding

933 

15,652 

 

 

 

Additional paid-in capital - preferred

67,067 

1,217,348 

 

Common stock:

 

 

 

 

100,000,000 common shares, $0.001 par value

 

 

 

 

22,701,904 and 5,566,927 shares issued and outstanding

22,515 

5,380 

 

Additional paid-in capital

4,767,104 

1,182,933 

 

Common shares pending cancellation

187 

187 

 

Subscriptions payable

477,782 

299,063 

 

Retained deficit

(5,566,721)

(3,308,299)

 

 

Total Stockholders' Deficit

(231,133)

(587,736)

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

245,704 

$

96,295 



F-2




Cytta Corp.

Statements of Operations


 

 

 

For the Year Ended

 

For the Year Ended

 

 

 

September 30,

 

September 30,

 

 

 

2013

 

2012

 

 

 

 

 

 

REVENUES

$

2,800 

 

$

43,943 

 

 

 

 

 

 

 

Cost of sales

 

17,693 

 

 

 

 

 

 

GROSS MARGIN

2,800 

 

26,250 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

Professional fees

93,791 

 

113,775 

 

Management fees

369,990 

 

437,578 

 

General and administrative

1,802,275 

 

468,667 

 

Research and development

1,597 

 

715,711 

 

 

 

 

 

 

 

 

Total Operating Expenses

2,267,653 

 

1,735,731 

 

 

 

 

 

 

NET LOSS FROM OPERATIONS

(2,264,853)

 

(1,709,481)

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

Interest Income

6,431 

 

280 

 

Interest expense

 

(1,244)

 

 

Total other income (expense)

6,431 

 

(964)

 

 

 

 

 

 

NET LOSS BEFORE TAXES

(2,258,422)

 

(1,710,445)

 

 

 

 

 

 

 

Provision for income taxes

 

NET LOSS

$

(2,258,422)

 

$

(1,710,445)

 

 

 

 

 

 

PER SHARE DATA:

 

 

 

 

 

 

 

 

 

 

Basic and diluted income

 

 

 

 

 

(loss) per common share

$

(0.10)

 

$

(0.31)

 

 

 

 

 

 

 

Weighted average number of

 

 

 

 

 

common shares outstanding

22,701,905 

 

5,528,038 



F-3




Cytta Corp.

Statements of Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

Preferred Stock

 

Paid-in

 

Common Stock

 

Paid-in

 

 

 

Retained

 

Stockholders'

 

 

Shares

 

Amount

 

Capital

 

Shares

 

Amount

 

Segregated

 

Capital

 

Subscriptions

 

(Deficit)

 

(Deficit)

Balance - September 30, 2011

4,751,536 

 

$

4,752 

 

$

296,248 

 

5,333,594

 

$

5,147

 

$

187

 

$

1,092,166

 

$

6,000 

 

$

(1,597,854)

 

 $      (189,354)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred shares issued for cash at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.10 per share, December 1, 2011

3,000,000 

 

3,000 

 

297,000 

 

-

 

-

 

-

 

-

 

 

 

           300,000

Common shares issued for services at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.39 per share, December 1, 2011

 

 

 

233,333

 

233

 

-

 

90,767

 

 

 

             91,000

Preferred shares issued for services at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.08 per share, January 2, 2012

7,900,000 

 

7,900 

 

624,100 

 

-

 

-

 

-

 

-

 

 

 

           632,000

 Preferred stock subscriptions

 

 

 

-

 

-

 

-

 

-

 

293,063 

 

 

           293,063

(Loss) for the year

 

 

 

-

 

-

 

-

 

-

 

 

(1,710,445)

 

      (1,710,445)

Balance - September 30, 2012

15,651,536 

 

$

15,652 

 

$

1,217,348 

 

5,566,927

 

$

5,380

 

$

187

 

$

1,182,933

 

$

299,063 

 

$

(3,308,299)

 

 $      (587,736)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Beneficial interest - Warrants

 

 

 

-

 

-

 

-

 

-

 

128,700 

 

 

           128,700

 Common stock subscriptions

 

 

 

-

 

-

 

-

 

-

 

175,100 

 

 

           175,100

Common shares issued for

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

subscriptions, January 1, 2013

 

 

 

670,833

 

671

 

-

 

250,892

 

(251,563)

 

 

                      -

Common shares issued for services at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.27 per share, February 21, 2013

 

 

 

633,333

 

633

 

-

 

173,260

 

 

 

           173,893

Common shares issued for

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

subscriptions, February 21, 2013

 

 

 

843,333

 

843

 

-

 

179,257

 

(180,100)

 

 

                      -

Preferred shares converted to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

common, February 21, 2013

(3,000,000)

 

(3,000)

 

(297,000)

 

1,000,000

 

1,000

 

-

 

299,000

 

 

 

                      -

Preferred shares converted to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

common, March 21, 2013

(7,300,000)

 

(7,300)

 

(576,700)

 

2,433,333

 

2,433

 

-

 

581,567

 

 

 

                      -

Preferred shares converted to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

common, March 22, 2013

(4,418,186)

 

(4,418)

 

(276,582)

 

1,472,729

 

1,473

 

-

 

279,527

 

 

 

                      -

Common shares issued for services at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.278per share, June 24, 2013

 

 

 

200,000

 

200

 

-

 

55,400

 

 

 

             55,600

 Common stock subscriptions

 

 

 

-

 

-

 

-

 

-

 

293,200 

 

 

           293,200

Debt converted to common

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 stock subscriptions

 

 

 

-

 

-

 

-

 

-

 

624,532 

 

 

           624,532



F-4





Common shares issued for

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

subscriptions, September 30, 2013

 

 

 

4,051,416

 

4,051

 

-

 

607,099

 

(611,150)

 

 

                      -

Common shares issued for services at

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$0.20 per share, September 30, 2013

 

 

 

5,820,000

 

5,820

 

-

 

1,158,180

 

 

 

        1,164,000

(Loss) for the year

 

 

 

-

 

-

 

-

 

-

 

 

(2,258,422)

 

      (2,258,422)

Balance - September 30, 2013

933,350

 

$

934

 

$

67,066 

 

22,691,904

 

$

22,505

 

$

187

 

$

4,767,114

 

$

477,782 

 

$

(5,566,721)

 

 $      (231,133)






F-5




Cytta Corp.

Statements of Cash Flows

 

 

 

 

For the Years Ended

 

 

 

 

September 30,

 

 

 

 

2013

 

2012

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net income (loss)

$

(2,258,422)

 

$

(1,710,445)

 

Adjustments to reconcile net income (loss) to net

 

 

 

 

cash from operating activities:

 

 

 

 

 

Depreciation and amortization

3,809 

 

3,160 

 

 

Issuance of common stock

 

 

 

 

 

 

for services and expenses

1,393,493 

 

91,000 

 

 

Issuance of preferred stock

 

 

 

 

 

 

for services and expenses

 

632,000 

 

 

Beneficial interest-Warrants

128,700 

 

 

Changes in Operating Assets and Liabilities:

 

 

 

 

 

Inventory

 

3,486 

 

 

Accounts receivable

(200)

 

 

 

Accounts payable and accrued liabilities

(12,334)

 

4,441 

 

 

Due to related parties

428,472 

 

370,500 

 

 

 

Net cash from operating activities

(316,482)

 

(605,858)

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Note receivable

3,853 

 

(23,835)

 

Loan to shareholder

 

(17,500)

 

Equipment

(4,883)

 

(6,489)

 

 

Net cash from investing activities

(1,030)

 

(47,824)

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

Preferred stock issued for cash

 

300,000 

 

Proceeds from common stock subscriptions

468,300 

 

293,063 

 

 

Net cash from financing activities

468,300 

 

593,063 

 

 

 

 

 

 

 

NET CHANGE IN CASH

150,788 

 

(60,619)

CASH AT BEGINNING OF PERIOD

37,280 

 

97,899 

CASH AT END OF PERIOD

$

188,068 

 

$

37,280 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW DISCLOSURES

 

 

 

 

Cash paid for interest

$

 

$

 

Cash paid for income taxes

$

 

$

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

Common stock subscriptions for debt

$

624,532 

 

$

 

Common stock issued for MVNO license

$

 

$




F-6




Cytta Corp.

Notes to Financial Statements

September 30, 2013 and 2012


NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS


Cytta Corp., (the “Company”) was incorporated on May 30, 2006 under the laws of the State of Nevada. It is located in Las Vegas, Nevada. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is September 30. Currently, the Company is in engaged in the manufacture, distribution and marketing of various telephony based internet access and computing products and services in the eHealth industry.


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Basis of Presentation


The accompanying audited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.  


Use of Estimates


The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s periodic filings with the Securities and Exchange Commission include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.


Cash and Cash Equivalents


Cash and cash equivalents include cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. The Company had $188,068 and $36,080 in cash and cash equivalents at September 30, 2013 and 2012 respectively.


Start-Up Costs


In accordance with ASC 720-15-20, “Start-up Activities”, the Company expenses all costs incurred in connection with the start-up and organization of the Company.


Impairment of long-lived assets


The Company follows the provisions of ASC 360 for its long-lived assets. The Company’s long-lived assets, which include test equipment and purchased intellectual property rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.




F-7






The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.


Fair value of financial instruments


The Company follows ASC 825 in accounting for its financial instruments. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties. The carrying amounts of financial assets and liabilities, such as accrued expenses, approximate their fair values because of the short maturity of these instruments. The Company’s notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangement at September 30, 2013 and 2012.


Risks and Uncertainties


The Company operates in the technology industry which is subject to significant risks and uncertainties, including financial, operational, technological, and other risks associated with operating a technology business, including the potential risk of business failure.


Revenue recognition


The Company follows the guidance of ASC 605 for revenue recognition. The Company will recognize revenues when it is realized or realizable and earned less estimated future doubtful accounts. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. The Company has earned no revenues since inception.


Stock-based compensation


The Company accounted for its stock based compensation under the recognition and measurement principles of the fair value recognition provisions of Statement of Financial Accounting Standards No. 123 (revised 2004) “Share-Based Payment” (“SFAS No. 123R”)(ASC 718) using the modified prospective method for transactions in which the Company obtains employee services in share-based payment transactions and the Financial Accounting Standards Board Emerging Issues Task Force Issue No. 96-18 “Accounting For Equity Instruments That Are Issued To Other Than Employees For Acquiring, Or In Conjunction With Selling Goods Or Services” (“EITF No. 96-18”) for share-based payment transactions with parties other than employees provided in SFAS No. 123(R) (ASC 718).  All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the third-party performance is complete or the date on which it is probable that performance will occur.



F-8






Income taxes


The Company accounts for income taxes under Statement of Financial Accounting Standards No. 109 “Accounting for Income Taxes” (“SFAS No. 109”) (ASC 740). Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.


Cash flows reporting


The Company follows the provisions of ASC 230 for cash flows reporting and accordingly classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by ASC 230 to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.


Reporting segments


ASC 280 establishes standards for the way that public enterprises report information about operating segments in annual financial statements and requires reporting of selected information about operating segments in interim financial statements regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performances. Currently, ASC 280 has no effect on the Company’s consolidated financial statements as substantially all of the Company’s operations are conducted in one industry segment.


Concentrations of Credit Risk


The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.



F-9






Earnings (Loss) Per Share of Common Stock


The Company has adopted ASC 260-10-20, “Earnings per Share,” (“EPS”) which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.


Recent Accounting Pronouncements


The Company has evaluated the recent accounting pronouncements through ASU 2013-10 and believes that none of them will have a material effect on the company’s financial statements.


NOTE 3 - CAPITAL STOCK


Authorized Stock


At inception, the Company had authorized 100,000,000 common shares and 100,000,000 preferred shares, both with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.


Effective July 1, 2009, the Company increased the number of authorized shares to 2,000,000,000 shares, of which 1,900,000,000 shares are designated as common stock with a par value of $0.00001 per share, and 100,000,000 shares are designated as preferred stock with a par value of $0.001 per share.


Effective November 7, 2012, the Company increased the number of authorized shares to 4,000,000,000 shares, of which 3,900,000,000 shares are designated as common stock with a par value of $0.00001 per share, and 100,000,000 shares are designated as preferred stock with a par value of $0.001 per share.


As of April 9, 2013 the Company reverse split its common shares 1 for 300 reducing the number of authorized common shares to 13,000,000. All common stock disclosures appearing in the accompanying financial statements have been retroactively restated to reflect the reverse split of shares. The Company increased the number of authorized common shares to 100,000,000 with a $0.001 par value.


Share Issuances


On November 18, 2008, the Company effected a 4 for 1 forward split, of its common stock, under which each stockholder of record, received 4 new shares of the Corporation’s stock for every one share outstanding.


On June 19, 2009, the Company effected a 20 for 1 forward split, of its common stock, under which each stockholder of record on July 10, 2009, received 20 new shares of the Corporation’s stock for every one share outstanding.


As of April 9, 2013 the Company reverse split its common shares 1 for 300 reducing the number of authorized common shares to 13,000,000. All common stock disclosures appearing in the accompanying financial statements have been retroactively restated to reflect the reverse split of shares. The Company increased the number of authorized common shares to 100,000,000 with a $0.001 par value.




F-10





56,000,000 shares are pending cancellation. These shares were issued and subsequently cancelled when the merger with Ophthalmic International, Inc. was rescinded. However, the physical certificate was lost and thus it is being disclosed separately in our share capital. The shares have legally been cancelled as to our transfer agent.


Management has placed a stop with our transfer agent and will not permit these shares to be negotiated, but are still outstanding until the physical certificate can be surrender or reissued.


As of September 30, 2013 the Company had issued and outstanding 933,350 preferred shares and 22,701,904 common shares.


NOTE 4 - INCOME TAXES


The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.


The Company is subject to income taxes under the laws of United States of America. The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 35% to the net loss before provision for income taxes for the following reasons:


 

September 30,

 

2013

 

2012

Income tax expense (benefit) at statutory rate

$

(790,448)

 

$

(598,656)

Stock based expenses

 

Valuation allowance

790,448 

 

598,656 

Income tax expense per books

$

 

$


Net deferred tax assets consist of the following components as of:


 

September 30,

 

2013

 

2012

NOL Carryover

$

5,566,721 

 

$

3,308,299 

Valuation allowance

(5,566,721)

 

(3,308,299)

Net deferred tax asset

$

 

$


Due to the change in ownership provisions of the Income Tax laws of the United States, net operating loss carry forwards of approximately $5,566,721 for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur net operating loss carry forwards may be limited as to use in future years.


NOTE 5 - DUE TO RELATED PARTIES


As of September 30, 2013 and 2012, the Company was obligated to related parties for a non-interest bearing demand loans with balances totaling of $469,672 and $664,532. On September 30, 2013 the related parties converted $624,532 of debt into common stock subscriptions payable.




F-11






NOTE 6 - GOING CONCERN AND LIQUIDITY CONSIDERATIONS


The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As at September 30, 2013, the Company had a loss from operations of $2,258,422, a retained deficit of $5,566,721 and a working capital deficit of $288,569.


In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.


NOTE 7 - SUBSEQUENT EVENTS


On October 15, 2013 the Company issued 3,000,000 common shares for services.


On October 15, 2013 the Company received $10,000 in common stock subscriptions.


On October 21, 2013 the Company converted $423,868 in related party debt to subscriptions payable.


In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and there are no additional subsequent events to report.






F-12